戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rtWare ventricular assist device system as a bridge to transplantation.
2 e oxygenation or mechanical ventilation as a bridge to transplantation.
3 required ECMO and 22 (4.1%) required MV as a bridge to transplantation.
4 primary indication for MCS therapy supported bridge to transplantation.
5  standard in the United States for pediatric bridge to transplantation.
6 uous-flow left ventricular assist device for bridge to transplantation.
7 t placement of the Micromed DeBakey VAD as a bridge to transplantation.
8 in children until improvement occurs or as a bridge to transplantation.
9 icular assist device (LVAD) is inserted as a bridge to transplantation.
10 cted patients who received this therapy as a bridge to transplantation.
11 nd short-term mechanical circulatory support bridge to transplantation.
12 acute liver failure to provide stability and bridge to transplantation.
13             Nine patients were successfully "bridged" to transplantation.
14 tion pumps is a well-established therapy for bridging to transplantation.
15        The indications for LVAS support were bridge to transplantation (54%) or destination therapy (
16                 The cohort was predominantly bridge-to-transplantation (67%), with median age of 59 y
17 sed significantly in recent years, both as a bridge to transplantation and as destination therapy in
18              Patients enrolled into the HMII bridge to transplantation and destination therapy trials
19                    Traditionally viewed as a bridge to transplantation and more recently as a destina
20                       They were successfully bridged to transplantation and received heart transplant
21 rrelation between the proportion of patients bridged to transplantation and the proportion of patient
22 trated with LVAD unloading alone in patients bridged to transplantation and those occurring in the my
23 rs, 87.7% of the implants were intended as a bridge to transplantation, and median length of support
24 % had an ischemic cardiomyopathy, 87.7% were bridge to transplantation, and median length of support
25 nts with advanced heart failure, either as a bridge to transplantation, as destination therapy, or in
26 ve review of patients receiving a mechanical bridge to transplantation at Columbia Presbyterian Hospi
27 tricular assist systems (LVASs) are used for bridging to transplantation, bridging to myocardial impr
28 horatec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destinatio
29                                              Bridge to transplantation (BTT) with left ventricular as
30 ere liver trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as definitive thera
31 g Administration approved the HM II LVAD for bridge to transplantation (BTT).
32 imed to evaluate the cost-effectiveness of a bridge-to-transplantation (BTT)-VAD approach relative to
33        This initial experience suggests that bridging to transplantation can be successfully approach
34    LVRS should not be easily considered as a bridge to transplantation for all lung transplant candid
35 tients underwent implantation of a HMII as a bridge to transplantation from March 2005 to March 2007.
36          Mechanical circulatory support as a bridge to transplantation has allowed patients with adva
37 ch devices in the short and medium term as a bridge to transplantation has led to their evaluation as
38  experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of suc
39 tion of left ventricular assist devices as a bridge-to-transplantation have resulted in HLA sensitiza
40                            Data on VADs as a bridge to transplantation in children are limited.
41 he adjunct efficacy of Sorafenib to Y90 as a bridge to transplantation in hepatocellular carcinoma (H
42 us inotropic therapy can be safely used as a bridge to transplantation in pediatric patients.
43  portocaval shunting has been described as a bridge to transplantation in the most severe cases, as w
44 l date of the first continuous-flow LVAD for bridge to transplantation in the United States (2008).
45 f left ventricular assist devices (LVADs) as bridges to transplantation is successful, the issue of p
46 ), which was originally used clinically as a bridge to transplantation, may also be used as destinati
47 hospital after LVAD implantation in the HMII bridge to transplantation (n = 405) and destination ther
48 ut severe comorbidity for whom dialysis is a bridge to transplantation or a long-term maintenance tre
49 , and January 1, 2010, as part of either the bridge to transplantation or destination therapy trials
50 mp irrespective of the intended goal of use (bridge to transplantation or destination therapy).
51  regardless of the intended goal of support (bridge to transplantation or destination therapy).
52 ective of the intended goal of pump support (bridge to transplantation or destination therapy).
53 r bridge to myocyte recovery, as well as for bridge to transplantation or long-term support.
54         Eight-two patients (55%) were either bridged to transplantation, recovery or are ongoing and
55 c reserve, the shunt was used as a long-term bridge to transplantation (shunt group 1).
56                                  Among those bridged to transplantation, survival in the intended goa
57                 We review recent advances in bridge-to-transplantation therapy, including the use of
58 anslation of this strategy into clinics as a bridge-to-transplantation therapy.
59 ollowing extracorporeal membrane oxygenation bridging to transplantation under the new system achieve
60 were scheduled for placement of an LVAD as a bridge to transplantation underwent bone marrow aspirati
61 (HR=2.011, 95% CI=1.069-3.784; P=0.030) as a bridge to transplantation was independently associated w
62 nths); 28% had cardiomyopathy; and in 38%, a bridge to transplantation was intended at ECMO initiatio
63 o had received a total artificial heart as a bridge to transplantation were 86 and 64 percent.
64 us eliminating problems commonly seen in the bridge to transplantation with left ventricular and bive
65 In the recent era (2000 to 2003), successful bridge to transplantation with VAD was achieved in 86% o
66  Pediatric heart transplant patients (n=106) bridged to transplantation with EXCOR were compared with
67                                              Bridging to transplantation with an implantable LVAD imp
68 eart allocation system on survival following bridging to transplantation with venous-arterial extraco
69 dvanced heart failure patients who are being bridged to transplantation, without evidence of detrimen